-->

Tag: Dostarlimab-gxly

Home / Dostarlimab-gxly

Categories

Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer

Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progr...
dostarlimab-gxly

Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or a...
dostarlimab-gxly

Scan the code